CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD

P-O Bridevaux¹, M W Gerbase¹, N M Probst-Hensch², C Schindler³, J-M Gaspoz⁴, T Rochat¹

¹ Division of Pulmonary Medicine, Geneva University Hospitals and University of Geneva, Switzerland
² Molecular Epidemiology/Cancer Registry, Institutes of Social and Preventive Medicine and Surgical Pathology, University of Zurich, Switzerland
³ Institute of Social and Preventive Medicine, University of Basle, Switzerland
⁴ Division of Community Medicine and Primary Care, University Hospitals of Geneva, University of Geneva Medical School, Switzerland

Dr P-O Bridevaux, University Hospitals of Geneva, Division of Pulmonary Medicine, 24 rue Micheli-du-Crest, 1211 Geneva, Switzerland; Pierre-Olivier.Bridevaux{at}hcuge.ch

Background: Little is known about the long-term outcomes of individuals with mild chronic obstructive pulmonary disease (COPD) as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

Methods: A population cohort of 6671 randomly selected adults without asthma was stratified into categories of modified GOLD-defined COPD (prebronchodilator spirometry). Further stratification was based on the presence or absence of respiratory symptoms. After 11 years, associations between baseline categories of COPD and decline in forced expiratory volume in 1 s (FEV₁), respiratory care utilisation and quality of life as measured by the SF-36 questionnaire were examined after controlling for age, sex, smoking and educational status.

Results: At baseline, modified GOLD criteria were met by 610 (9.1%) participants, 519 (85.1%) of whom had stage 1 COPD. At follow-up, individuals with symptomatic stage 1 COPD (n = 224) had a faster decline in FEV₁ (–9 ml/year (95% CI –13 to –5)), increased respiratory care utilisation (OR 1.6 (95% CI 1.0 to 2.6)) and a lower quality of life than asymptomatic subjects with normal lung function (n = 3627, reference group). In contrast, individuals with asymptomatic stage 1 COPD (n = 295) had no significant differences in FEV₁ decline (–3 ml/year (95% CI –7 to +1)), respiratory care utilisation (OR 1.05 (95% CI 0.63 to 1.73)) or quality of life scores compared with the reference group.

Conclusions: In population-based studies, respiratory symptoms are of major importance for predicting long-term clinical outcomes in subjects with COPD with mild obstruction. Population studies based on spirometry only may misestimate the prevalence of clinically relevant COPD.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Airwaves

Wisia Wedzicha
Thorax 2008 63: 1. [Extract] [Full Text] [PDF]

What evidence could validate the definition of COPD?

Roberto de Marco
Thorax 2008 63: 756-757. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• de Marco, R., Accordini, S., Anto, J. M., Gislason, T., Heinrich, J., Janson, C., Jarvis, D., Kunzli, N., Leynaert, B., Marcon, A., Sunyer, J., Svanes, C., Wjst, M., Burney, P. (2009). Long-Term Outcomes in Mild/Moderate Chronic Obstructive Pulmonary Disease in the European Community Respiratory Health Survey. Am. J. Respir. Crit. Care Med. 180: 956-963 [Abstract] [Full Text]  
• Bridevaux, P-O., Gerbase, M., Rochat, T. (2009). From the authors:. Eur Respir J 34: 777-777 [Full Text]  
• Enright, P L (2009). GOLD stage 1 is crying wolf. Thorax 64: 182-183 [Full Text]  
• Bridevaux, P-O, Gerbase, M W, Rochat, T (2009). Authors' reply. Thorax 64: 183-183 [Full Text]  
• de Marco, R. (2008). What evidence could validate the definition of COPD?. Thorax 63: 756-757 [Full Text]